asurgeryАмбулаторная хирургияAmbulatornaya khirurgiya = Ambulatory Surgery (Russia)2712-87412782-2591ООО «ГРУППА РЕМЕДИУМ»10.21518/1995-14772018-1-2-26-31asurgery-105Research ArticleФЛЕБОЛОГИЯ | АНГИОЛОГИЯPHLEBOLOGY | ANGIOLOGYФармакотерапия хронической венозной недостаточности нижних конечностейPharmacotherapy of chronic venous insufficiency of the lower extremitiesДженинаО. В.DzheninaO. V.noemail@neicon.ruЛобановВ. Н.LobanovV. N.noemail@neicon.ruГордеевВ. С.GordeevB. S.noemail@neicon.ruПервый флебологический центрРоссияFirst PhLeboLogicaL CenterRussian Federation20182006201801-22631Copyright © Дженина О.В., Лобанов В.Н., Гордеев В.С., 20182018Дженина О.В., Лобанов В.Н., Гордеев В.С.Dzhenina O.V., Lobanov V.N., Gordeev B.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.a-surgeon.ru/jour/article/view/105

Хроническая венозная недостаточность (ХВН) - самая распространенная патология периферической сосудистой системы. Фармакотерапия с использованием веноактивных препаратов - один из основных принципов консервативного лечения как малых, так и осложненных форм. Эффективность терапии во многом связана с выбором флеботропного препарата. Рассмотрены подходы к системной и топической медикаментозной терапии в зависимости от формы и стадии ХВН.

Chronic venous insufficiency (CVI) is the most common pathology of the peripheral vascular system. One of the main principles of conservative treatment for both small and complicated forms is pharmacotherapy with the use of venoactive drugs. The effectiveness of therapy is largely associated with the choice of phlebotrophic drug. The article discusses approaches to systemic and topical drug therapy depending on the form and stage of CVI.

хроническая венозная недостаточностьвеноактивные препаратыФЛПМОФФдиосминместное лечениеchronic venous insufficiencyvenoactive drugsphlebology drugmicronized purified flavonoid fractiondiosminlocal treatmentReferencesRabe E, Guex J-J, Puskas A, Scuderi A, Fernandez Quesada F. The VCP Coordinators Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol, 2012, 31 (2): 105-115.Rabe E, Guex J-J, Puskas A, Scuderi A, Fernandez Quesada F. The VCP Coordinators Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol, 2012, 31 (2): 105-115.Pitsch F. VEIN CONSULT Program: interim results from the first 70 000 screened patients in 13 countries. Phlebolympholog, 2012, 19 (3): 132.Pitsch F. VEIN CONSULT Program: interim results from the first 70 000 screened patients in 13 countries. Phlebolympholog, 2012, 19 (3): 132.Eberhardt R, Raffetto J. Chronic Venous Insuffiency. Circulation, 2014, 130: 333-346.Eberhardt R, Raffetto J. Chronic Venous Insuffiency. Circulation, 2014, 130: 333-346.Nicolaides A. Investigation of Chronic Venous Insuffiency. Circulation, 2000, 102: 126-163.Nicolaides A. Investigation of Chronic Venous Insuffiency. Circulation, 2000, 102: 126-163.Graham ID, Harrison MB, Nelson EA, et al. Prevalence oflowerlimb ulceration: a systematic review of prevalence studies. Adv Scin Wound Care, 2003, 16: 305-316.Graham ID, Harrison MB, Nelson EA, et al. Prevalence oflowerlimb ulceration: a systematic review of prevalence studies. Adv Scin Wound Care, 2003, 16: 305-316.Rybak Z. Management oflower-limb venous symptoms: what the guidelines tell us. Medicographia, 2015, 37: 50-55.Rybak Z. Management oflower-limb venous symptoms: what the guidelines tell us. Medicographia, 2015, 37: 50-55.Mellor RH, Brice G, Stanton AW, et al. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lowerlimbs. Circulation, 2007, 115: 1912-1920.Mellor RH, Brice G, Stanton AW, et al. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lowerlimbs. Circulation, 2007, 115: 1912-1920.Serra R, Buffone G, de Franciscis A, et al. A genetic study of chronic venous insufficiency. Ann Vasc Surg, 2012, 26: 636-642.Serra R, Buffone G, de Franciscis A, et al. A genetic study of chronic venous insufficiency. Ann Vasc Surg, 2012, 26: 636-642.Krysa J, Jones GT and van Rij AM. Evidence for a genetic role in varicose veins and chronic venous insufficiency. Phlebology, 2012, 27 ( 7): 3 29-335.Krysa J, Jones GT and van Rij AM. Evidence for a genetic role in varicose veins and chronic venous insufficiency. Phlebology, 2012, 27 ( 7): 3 29-335.Kucukguven A, Khalil RA. Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets, 2013, 14 (3): 287-324.Kucukguven A, Khalil RA. Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets, 2013, 14 (3): 287-324.Boisseau M-R. Chronic venous disease and the genetic influence. Phlebolymphology, 2014, 21 (2): 100. выбор веноактивного препарата с учетом генеза и стадии патологического процесса позволяет получить стойкий положительный результат, увеличить длительность периода ремиссии, предотвратить прогрессирование венозной недостаточности и в итоге улучшить качество жизни пациентов. Конфликт интересов: авторы заявляют об отсутствии конфликта интересов в ходе написания данной статьи.Boisseau M-R. Chronic venous disease and the genetic influence. Phlebolymphology, 2014, 21 (2): 100. выбор веноактивного препарата с учетом генеза и стадии патологического процесса позволяет получить стойкий положительный результат, увеличить длительность периода ремиссии, предотвратить прогрессирование венозной недостаточности и в итоге улучшить качество жизни пациентов. Конфликт интересов: авторы заявляют об отсутствии конфликта интересов в ходе написания данной статьи.Raffeto JD, Mannello F. Pathophysiology of chronic venous disease. Int Angiol, 2014, 33 (3): 212-21.Raffeto JD, Mannello F. Pathophysiology of chronic venous disease. Int Angiol, 2014, 33 (3): 212-21.Bergan JJ, Schmid-Schonbein GW, Coleridge-Smith PD. Chronic venous disease. N Engl J Med. 2006, 355 (3): 488-96.Bergan JJ, Schmid-Schonbein GW, Coleridge-Smith PD. Chronic venous disease. N Engl J Med. 2006, 355 (3): 488-96.Wittens С, Davies AH, Bskgaard N, Broholm R, Cavezzi A, et al. Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg, 2015, 49: 678-737.Wittens С, Davies AH, Bskgaard N, Broholm R, Cavezzi A, et al. Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg, 2015, 49: 678-737.Nicolaides A, Kakkos S, Eklof B, et al. Management of chronic venous disorders of thelowerlimbs. Guidelines according to scientific evidence. Int Angiol. 2014, 33 (2): 87-208.Nicolaides A, Kakkos S, Eklof B, et al. Management of chronic venous disorders of thelowerlimbs. Guidelines according to scientific evidence. Int Angiol. 2014, 33 (2): 87-208.Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен. Флебология, 2013, 7 (2): 2-47./Russian clinical guidelines for diagnosis and treatment of chronic venous diseases. Phlebology, 2013, 7 (2): 2-47.Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен. Флебология, 2013, 7 (2): 2-47./Russian clinical guidelines for diagnosis and treatment of chronic venous diseases. Phlebology, 2013, 7 (2): 2-47.Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg, 2011, 41: 117-125.Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg, 2011, 41: 117-125.Nicolaides A, Allegra C, Bergan J, et al. Management of Chronic Venous Disorders of the Lower Limbs: Guidelines According to Scientific Evidence. Int Angiol, 20 08, 27 (1): 1-59.Nicolaides A, Allegra C, Bergan J, et al. Management of Chronic Venous Disorders of the Lower Limbs: Guidelines According to Scientific Evidence. Int Angiol, 20 08, 27 (1): 1-59.Martinez M J, Bonfill X, Moreno R M, Vargas E, Capella D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev, 2005: CD003229.Martinez M J, Bonfill X, Moreno R M, Vargas E, Capella D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev, 2005: CD003229.Ramelet A-A, Boisseau M R, Allegra C, Nicolaides A, et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc, 2005, 33 (4): 309-319.Ramelet A-A, Boisseau M R, Allegra C, Nicolaides A, et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc, 2005, 33 (4): 309-319.Colerige-Smith P, Lok C, Ramelet A-A. Venousleg ulcer: a metaanalysis of adjunctive therapy with micronized purified flavo-noid fraction. Eur J Vasc Endovasc Surg, 2005, 30: 198-208.Colerige-Smith P, Lok C, Ramelet A-A. Venousleg ulcer: a metaanalysis of adjunctive therapy with micronized purified flavo-noid fraction. Eur J Vasc Endovasc Surg, 2005, 30: 198-208.Gloviczki P. Handbook of Venous Disorders Guidelines of the American Venous Forum, Third Edition 2009.Gloviczki P. Handbook of Venous Disorders Guidelines of the American Venous Forum, Third Edition 2009.

The authors declare that there are no conflicts of interest present.